Morgan Stanley analyst Terence Flynn raised the firm’s price target on United Therapeutics (UTHR) to $519 from $471 and keeps an Equal Weight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics initiated with an Outperform at Raymond James
- United Therapeutics announces FDA granted RMAT designation to miroliverELAP
- United Therapeutics price target raised to $700 from $643 at RBC Capital
- United Therapeutics price target raised to $660 from $600 at H.C. Wainwright
- United Therapeutics price target raised to $626 from $569 at BofA